Search Results
Your search for s matches 6865 pages
Showing 1951 - 2000Healthy Lifestyle for Young Adult Cancer Survivors
GUEST EDITOR Integrative Oncology is guest edited by Jun J. Mao, MD, MSCE, Laurance S. Rockefeller Chair in Integrative Medicine and Chief of Integrative Medicine Service at Memorial Sloan Kettering Cancer Center, New York. The survival rates of adolescent and young adults with cancer have risen ...
Oral Antibiotics and Risk of Colon or Rectal Cancer
In an extensive data mining analysis of British medical records, researchers found that taking even a single course of antibiotics might boost—albeit slightly—the risk of developing colon cancer, but not rectal cancer, a decade later. The findings, reported by Zhang et al in Gut,...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
Racial Reporting and Representation in Oncology Trials
New research published by Loree et al in JAMA Oncology found that race and race subgroup analysis reporting does not occur frequently and that black and Hispanic populations are underrepresented in oncology trials that have led to U.S. Food and Drug Administration (FDA) approvals. The study raises...
Adavosertib Plus Gemcitabine and Radiotherapy in Locally Advanced Pancreatic Cancer
In a phase I dose-escalation trial reported in the Journal of Clinical Oncology, Cuneo et al established the phase II dose of the Wee1 kinase inhibitor adavosertib in combination with gemcitabine and radiotherapy in locally advanced pancreatic cancer. Wee1 inhibition impedes DNA damage response and ...
T-Cell Receptor Gene Therapy in HPV-Associated Epithelial Cancers
In a first-in-human phase I/II study reported in the Journal of Clinical Oncology, Doran et al found that autologous genetically engineered T cells expressing a T-cell receptor directed against the human papillomavirus (HPV)16 E6 oncoprotein were capable of inducing tumor regression in metastatic,...
Relationship Between Sleep Apnea and Cancer Risk in Women
Women with severe sleep apnea appear to also have an elevated risk of developing cancer, according to findings from a study by Pataka et al in the European Respiratory Journal. No causal relationship was demonstrated, but a link between nocturnal hypoxia in women and higher cancer risk was...
NCORP Expands to More Sites
The National Cancer Institute (NCI) has awarded 53 grants to researchers in the NCI Community Oncology Research Program (NCORP) to conduct multisite cancer clinical trials and cancer care delivery studies in their communities. In addition to seven research hubs, these NCI grants went to 32...
Mortality Risk for Patients With Preexisting Cardiovascular Conditions Treated With Abiraterone Acetate or Enzalutamide
A new population-based study showed that novel oral androgen signaling–inhibitor therapies may be associated with an increased risk of death in patients with preexisting cardiovascular conditions. The research was published by Lu-Yao et al in European Urology. “Data from published ...
FDA OCE and Syapse Announce Research Collaboration Focused on Regulatory Use of Real-World Evidence
Syapse and the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) have signed a multiyear research collaboration agreement focused on the use of real-world evidence to support regulatory decision-making. Syapse and the OCE will work with stakeholders across the FDA to...
FDA Pipeline: Designation in CLL, New Drug Application in GIST, New Prostate Ablation System Receives 510(k) Clearance
Recently, the U.S. Food and Drug Administration granted Breakthrough Therapy designation to acalabrutinib in chronic lymphocytic leukemia (CLL), accepted a new drug application for avapritinib in some types of gastrointestinal stromal tumors (GIST), and granted 501(k) clearance to market the...
FDA Approves Fedratinib for Myelofibrosis
Today, the U.S. Food and Drug Administration (FDA) approved fedratinib (Inrebic) for adults with intermediate-2 or high-risk primary or secondary (postpolycythemia vera or postessential thrombocythemia) myelofibrosis. “Prior to today, there was one FDA-approved drug to treat patients with...
FDA Approves Entrectinib for NTRK-Fusion Cancers, ROS1-Positive NSCLC
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to entrectinib (Rozlytrek) for adult and adolescent patients whose cancers have an NTRK (neurotrophic tyrosine receptor kinase) genetic fusion and for whom there are no effective treatments. Entrectinib was also...
CD8-Positive, Ki67-Positive T Cells Producing Interferon Gamma as a Biomarker of Response to Sorafenib Therapy in Patients With Advanced HCC
Immunology researchers have uncovered a biomarker that may help explain why some patients respond better than others to sorafenib, a common chemotherapy used in the treatment of hepatocellular carcinoma (HCC). Their analysis of immune responses among patients receiving sorafenib, published by...
FDA Review Finds No Increased Risk of Prostate Cancer With Parkinson's Disease Treatments Containing Entacapone
A U.S. Food and Drug Administration (FDA) review of additional data found no increased risk of prostate cancer with the use of entacapone to treat Parkinson’s disease. The FDA conducted this review after an earlier trial—the Stalevo Reduction in Dyskinesia Evaluation–Parkinson's...
Germline RABL3 Mutation May Increase Risk of Pancreatic Cancer Development
Scientists who studied a highly cancer-prone single family have identified a rare, inherited gene mutation that may raise the lifetime risk of pancreatic and other cancers. Their findings were published by Nissim et al in Nature Genetics. The discovery of the previously unknown mutation could lead ...
Addition of Cediranib to Cisplatin/Pemetrexed in Chemotherapy-Naive Unresectable Malignant Pleural Mesothelioma
In the phase II SWOG S0905 trial reported in the Journal of Clinical Oncology, Tsao et al found that the addition of the epidermal growth factor receptor and platelet-derived growth factor receptor inhibitor cediranib to cisplatin/pemetrexed was associated with limited benefit and greater toxicity...
Response- and Biology-Based Therapy for Pediatric Intermediate-Risk Neuroblastoma
As reported in the Journal of Clinical Oncology by Twist et al, use of reduced therapy for subsets of pediatric patients with intermediate-risk neuroblastoma in the Children’s Oncology Group (COG) study ANBL0531 did not affect the excellent overall survival rates observed in prior COG studies ...
Echinacea
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien Hou, PharmD, DipIOM, LAc, explores the potential health benefits of...
Circulating Tumor DNA Analysis for Detection of Residual Disease in Breast Cancer
Researchers have developed a new method for tracking residual disease in patients with breast cancer that could one day help doctors better tailor treatments and prevent unnecessary surgeries for some people with the disease. Findings were published by McDonald et al in Science Translational...
Can Genetic Counseling and Test Reporting in Patients Susceptible to Melanoma Development Change Behavior?
A new study published by Stump et al in Genetics in Medicine investigated whether genetic testing would motivate people at risk of developing melanoma to alter their behavior in order to reduce their risk. “We are trying to understand whether a genetic test result adds value over and above...
Conquer Cancer Honors Oncology Professionals With Merit Awards at the 2019 ASCO Annual Meeting
Conquer Cancer®, the ASCO Foundation, is pleased to announce the recipients of its 2019 ASCO Annual Meeting Merit Awards. These distinguished awards support oncology trainees who were first authors on abstracts selected for presentation at the ASCO Annual Meeting. This year, Conquer Cancer...
Highlights in Geriatric Hematology From the ASH Annual Meeting & Exposition
GUEST EDITOR Geriatrics for the Oncologist is guest edited by Stuart M. Lichtman, MD, FACP, FASCO, and developed in collaboration with the International Society of Geriatric Oncology (SIOG). Dr. Lichtman is an Attending Physician at Memorial Sloan Kettering Cancer Center, Commack, New York, and...
CMS Finalizes Decision to Cover CAR T-Cell Therapy for Medicare Beneficiaries
On August 7, the Centers for Medicare & Medicaid Services (CMS) finalized the decision to cover U.S. Food and Drug Administration (FDA)-approved chimeric antigen receptor (CAR) T-cell therapy among recipients of Medicare benefits. FDA-approved CAR T-cell therapies are approved to...
AACR Announces 2019 Class of Fellows of the AACR Academy
The American Association for Cancer Research (AACR) recently announced its newly elected class of Fellows of the AACR Academy. The mission of the AACR Academy is to recognize and honor distinguished scientists whose scientific contributions have propelled innovation and progress against cancer. The ...
Treatment Update on Selected Non-Hodgkin Lymphomas
As part of The ASCO Post’s coverage of the 2019 ASCO Annual Meeting, featured here are four abstracts from different clinical trials evaluating newer treatments for Waldenström’s macroglobulinemia and T-cell lymphomas. Waldenström’s Macroglobulinemia ABSTRACT 7509: Outcomes with bendamustine plus ...
Is Vitamin A Intake Linked to Cutaneous Squamous Cell Carcinoma Risk?
People whose diets included high levels of vitamin A had a 17% reduction in risk for developing cutaneous squamous cell carcinoma, as compared to those who ate modest amounts of foods and supplements rich in vitamin A. These findings were published by Kim et al in JAMA Dermatology. Vitamin A is...
Maintenance Bevacizumab, Pemetrexed, or Both in Advanced Nonsquamous NSCLC
In the phase III ECOG-ACRIN 5508 trial, reported in the Journal of Clinical Oncology by Ramalingam et al, maintenance pemetrexed or bevacizumab was associated with no significant improvement in overall survival vs the bevacizumab control group alone, and was associated with greater toxicity in...
Preserving Sexuality and Restoring Sexual Function in Male and Female Cancer Survivors
Intimacy changes after a cancer diagnosis. Both male and female survivors can experience significant sexual dysfunction, pain with sex, loss of desire, and a slew of other clinical and psychological sequelae. To make matter worse, sexual function is often not discussed by patients and their...
Notable Presentations at ASCO 2019 Included Studies in Sarcoma, Lymphoma, Myeloma, and Breast and Kidney Cancers
The 2019 ASCO Annual Meeting featured a wealth of presentations on important topics. In addition to our regular news coverage of the meeting, we present below some highlights of other studies that add to our knowledge base for treatment of various cancers. Olaratumab in Soft-Tissue Sarcoma...
How Treatment Costs Affect Decisions for Breast Cancer Surgery
In a study reported in the Journal of Oncology Practice, Greenup et al found that cancer treatment costs influenced women’s decisions on breast cancer surgery. Researchers reported many women, even at the highest income levels, said that costs were higher than expected, and that most women...
What Causes Liver Injury During Treatment With Pembrolizumab?
Immunotherapy as a treatment for advanced solid cancers has rapidly evolved over the past decade—often yielding remarkable results. However, its use has also given way to new adverse effects, including drug-induced gastrointestinal and liver toxicities. “Checkpoint inhibitors are a...
How an Innovative AI-Based Smartphone Application Is Addressing Patients’ Palliative Care Needs
GUEST EDITOR Addressing the evolving needs of cancer survivors at various stages of their illness and care, Palliative Care in Oncology is guest edited by Jamie H. Von Roenn, MD, FASCO. Dr. Von Roenn is ASCO’s Vice President of Education, Science, and Professional Development. During the 2019...
BEACON CRC: Encorafenib/Binimetinib/Cetuximab Improves Survival in BRAF V600E–Mutated Metastatic Colorectal Cancer
The three-drug combination of encorafenib (a BRAF inhibitor), binimetinib (a MEK inhibitor), and cetuximab (an EGFR inhibitor) significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer, according to the results of the phase III BEACON CRC clinical trial....
Tumor-Associated Antigen Cytotoxic T Cells in Relapsed or Refractory Solid Tumors
In a phase I trial reported in the Journal of Clinical Oncology, Hont et al found that treatment of relapsed or refractory solid tumors with ex vivo expanded autologous multiantigen-associated specific cytotoxic T cells—or, tumor-associated antigen cytotoxic T cells—was safe and showed...
FDA Approves Pexidartinib for Tenosynovial Giant Cell Tumor
On August 2, the U.S. Food and Drug Administration (FDA) granted approval to pexidartinib (Turalio) capsules for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with...
Adjuvant Radiotherapy After Radical Prostatectomy vs Radical Prostatectomy Alone in Patients With Positive Margins or Extracapsular Extension
In patients with prostate cancer with surgical positive margins or extracapsular extension of their disease, the risk of disease recurrence postprostatectomy is higher than in cases where the cancer cells are confined within the prostate. The Finnish FinnProstataX study investigated...
Global Burden of Pediatric and Adolescent Cancer in 2017
A recent analysis looked at the global burden of pediatric cancer through the lens of years of affected and lost life. This work shows a much greater burden of childhood cancer, placed largely in low- and middle-income countries, than previous estimates. The findings were published in The Lancet...
Survey Finds Majority of Americans Are Unfamiliar With Cutaneous Squamous Cell Carcinoma
Nearly-three quarters of Americans are not familiar with cutaneous squamous cell carcinoma, the second most common type of cancer in the United States, according to a new survey conducted by The Harris Poll on behalf of The Skin Cancer Foundation. Cutaneous squamous cell carcinoma is more common...
Ten-Year Update on Standard Adjuvant Chemotherapy vs Capecitabine in Older Women With Early Breast Cancer
As reported in the Journal of Clinical Oncology by Muss et al, long-term findings from the phase III CALGB 49907 trial support the finding from the primary analysis—that standard adjuvant chemotherapy improved recurrence-free survival vs capecitabine in women aged 65 years or older with early ...
FDA Approves Pembrolizumab for Some Patients With PD-L1–Positive Esophageal Cancer
On July 30, the U.S. Food and Drug Administration (FDA) approved the programmed cell death protein 1 inhibitor pembrolizumab (Keytruda) as monotherapy for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express programmed ...
WHO Releases Report on the Global Tobacco Epidemic
Many governments are making progress in the fight against tobacco, with 5 billion people today living in countries that have introduced smoking bans, warnings on packaging, and other effective tobacco control measures—four times more people than a decade ago. However, a new World Health...
Abdominal Fat and Mortality in Patients With Colorectal Cancer
For patients with colorectal cancer, new research shows a clearer connection than previously known between fat deposits in certain areas of the body and higher rates of death from all causes within 7 years of cancer diagnosis. These findings were published by Brown et al in the Journal of the...
Automated Breast Cancer Detection Assay Using Fine-Needle Aspiration May Aid Patients in Developing Countries
A new laboratory test developed to identify chemical changes to a group of cancer-related genes may be able to accurately detect which breast tumors are cancerous or benign. Such a test could result in a more timely diagnosis of breast cancer for women in developing countries with less access to...
Germline BRCA2 Mutations and Risk of Pediatric or Adolescent Lymphoma
A research letter published by Wang et al in JAMA Oncology has found that inherited mutations in the BRCA2 gene are linked to an increased risk for non-Hodgkin lymphoma in children and adolescents. “The BRCA family of genes are known to be linked to risk for breast and...
Conditional Reprogramming of Urine Cultures for Bladder Cancer
A research team led by investigators from Georgetown University Medical Center and Fudan University in China has devised a noninvasive and individualized technique for detecting and treating bladder cancer. Their findings were published by Jiang et al in Protein & Cell. The method uses a...
Deep Natural Language Processing of Oncology Radiology Reports
Scientists have demonstrated that an artificial intelligence (AI) tool can perform as well as human reviewers—and much more rapidly—in extracting clinical information regarding changes in tumors from unstructured radiology reports for patients with lung cancer. These findings were...
Pembrolizumab After Stereotactic Body Radiotherapy in Advanced NSCLC
In a Dutch phase II study reported in JAMA Oncology, Theelen et al found that although use of stereotactic body radiotherapy prior to pembrolizumab increased the objective response rate vs pembrolizumab alone in metastatic non–small cell lung cancer (NSCLC), the difference did not meet study...
ASCO Now Accepting Research Project Applications for Research Survey Pool
ASCO’S CENTER FOR Research and Analytics (CENTRA) is now accepting research applications from ASCO members who wish to conduct surveys of the Society’s membership for research purposes. The Research Survey Pool (RSP) is a service made available to ASCO members who engage in survey research. It...
ASCO, Conquer Cancer Congratulate 2019 Grant and Award Recipients
Conquer Cancer®, the ASCO Foundation, presented more than $7 million in grants and awards to exceptional oncology researchers at the 2019 ASCO Annual Meeting. ASCO and Conquer Cancer congratulate the recipients and offer their profound thanks to those who generously supported these awards. Visit...
